Oklahoma Health Care Authority Drug Utilization Review Board

(DUR Board)

Meeting –February 13, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority 2401 N.W. 23rd Street, Suite 1-A Oklahoma City, Oklahoma 73107 Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

<u>Items to be presented by Dr. Muchmore, Chairman:</u>

- 1. Call To Order
 - A. Roll Call Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item Approval of DUR Board Meeting Minutes See Appendix A.
 - A. January 9, 2013 DUR Minutes Vote
 - B. January 10, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

- 4. Action Item Update on DUR / Medication Coverage Authorization Unit See Appendix B.
 - A. Medication Coverage Activity for January 2013
 - B. Pharmacy Help Desk Activity for January 2013
 - C. Retrospective Drug Evaluation: Duplication of Narcotic Therapy
 - D. Vote on Brimonidine Safety Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 5. Action Item Vote to Update Antihyperlipidemics Prior Authorization Criteria, and Prior Authorize Vascepa™ and Juxtapid™ See Appendix C.
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 6. Action Item Vote to Prior Authorize Binosto[™] and Update Osteoporosis Medications Prior Authorization Criteria See Appendix D.
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 7. Action Item Vote to Prior Authorize Xeljanz® See Appendix E.
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 8. Action Item FY12 Annual Review of Narcotic Analgesics See Appendix F.
 - A. Background and Statistics Update
 - B. Current Authorization Criteria and Tier Structure
 - C. Utilization Review
 - D. Prior Authorization Review
 - E. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

- 9. 30 Day Notice to Prior Authorize Chronic Obstructive Pulmonary Disease Medications See Appendix G.
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 10. 30 Day Notice to Prior Authorize Miscellaneous Corticosteroid Products See Appendix H.
 - A. Summary
 - B. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 11. FDA and DEA Updates See Appendix I.
- 12. Future Business
 - A. Annual Reviews
 - B. New Product Reviews
- 13. Adjournment